2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08B.01 Heterogeneity of Peripheral Blood Cell Dynamics and Oncologic Outcomes Between LUAD and LUSC Receiving Neoadjuvant Immunochemotherapy

EP.08B.01 Heterogeneity of Peripheral Blood Cell Dynamics and Oncologic Outcomes Between LUAD and LUSC Receiving Neoadjuvant Immunochemotherapy

Back to course

Pdf Summary

The study examines the differences in peripheral blood cell dynamics and oncologic outcomes between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) in patients receiving neoadjuvant immunochemotherapy. Immune checkpoint inhibitors (ICIs)-based chemotherapy has shown significant benefits over traditional chemotherapy for early-stage non-small cell lung cancer (NSCLC), but responses between LUAD and LUSC remain understudied. This research aims to evaluate these differences by assessing baseline characteristics and peripheral blood immune cell dynamics in patients undergoing the treatment.<br /><br />Key findings indicate that patients treated with neoadjuvant immunotherapy exhibited promising pathological remission rates, especially those with LUSC, which showed a higher pathological complete response (PCR) rate. In LUAD, higher PD-L1 expression was linked to better PCR outcomes. Conversely, elevated white blood cell (WBC) counts after therapy suggested a lower probability of achieving PCR for LUSC.<br /><br />The retrospective study collected data from 301 patients (119 with LUAD, 182 with LUSC) treated at Guangdong Provincial People's Hospital. The research analyzed oncologic and surgical outcomes, biomarker data, and peripheral blood cell counts using various statistical methods. Significant differences in gender, smoking status, tumor stage, and pathological response rates were observed between the two groups. LUSC patients typically had more extensive surgeries, such as bilobectomy, contrasting with LUAD patients.<br /><br />For future research, the study suggests using multicenter prospective samples for better validation and employing a propensity score-matching design to clarify the clinical response characteristics further. The study underscores the complexity in treating LUAD and LUSC and highlights that different biomarkers may influence treatment outcomes, suggesting personalized treatment plans could be beneficial.

Asset Subtitle

Shaowei Wu

Meta Tag

Speaker Shaowei Wu

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

lung adenocarcinoma

lung squamous cell carcinoma

neoadjuvant immunochemotherapy

immune checkpoint inhibitors

pathological complete response

PD-L1 expression

peripheral blood cell dynamics

oncologic outcomes

non-small cell lung cancer

personalized treatment plans